News

Providence studies new therapy for patients with curable breast cancer

October 22, 2013
Providence Cancer Center is the only site in Oregon to open the KATHERINE study (NSABP B-50-I), evaluating the efficacy and safety of trastuzumab emtansine (Kadcyla) versus trastuzumab (Herceptin) as adjuvant (postoperative) therapy for breast cancer.

Providence Cancer Center first in nation to offer unique trial treatment for lymphoma patients

May 21, 2013

People with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia have a unique opportunity to participate in groundbreaking research at Providence Cancer Center.

An outpouring of giving: More than $400,000 boosts cancer research at Providence

May 17, 2013

Cancer survivors and researchers shared the stage at Providence Cancer Center’s 15th annual “Positive Perspectives: Creating Hope for Cancer Patients Luncheon” May 15 at the Oregon Convention Center.

NIH grant furthers promising metastatic melanoma clinical trials for Providence Cancer Center patients

March 15, 2013

Patients with advanced melanoma are getting a boost from work being done at Providence, thanks to a grant from the National Institutes of Health.

Early-phase clinical trials open new opportunities

January 16, 2013

Providence's involvement with the International Immuno-Oncology Network, along with other early-phase studies, is broadening treatment options for patients with advanced cancers.

Providence Cancer Center recognized for commitment to quality and excellence

September 28, 2012

Providence is the only cancer facility in Oregon to receive QOPI certification.

Pennies, nickels and dimes add up to $500,000 as Safeway customers and employees help Providence battle breast cancer

May 08, 2012

Safeway customers and employees in Oregon and Southwest Washington raised $500,000 for breast cancer awareness, treatment and research at Providence.

Providence selected for nationwide immunotherapy network

October 24, 2011

Providence Cancer Center is among North America's top research institutions invited to join the national Cancer Immunotherapy Trials Network.

Providence cancer drug trial wins FDA approval

April 11, 2011

Ipilimumab is the first drug shown to extend survival in patients with late-stage melanoma.